Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for obesity

 Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity

https://www.prnewswire.com/news-releases/lilly-releases-zepbound-tirzepatide-single-dose-vials-expanding-supply-and-access-for-adults-living-with-obesity-302230905.html